Windtree Announces Leadership Transition Plan With Industry Veterans [Yahoo! Finance]
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: Yahoo! Finance
the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has served as the CEO of Windtree since January of 2016 and oversaw numerous clinical studies, an uplisting to Nasdaq and several transactions and licenses as the Company became a late-stage cardiovascular-focused company. “In planning a transition, the question of timing as well as a successor has always been a key consideration for me,” said Mr. Fraser, current Chairman and CEO of Windtree. “The
Show less
Read more
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceGlobeNewswire
- Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia [Yahoo! Finance]Yahoo! Finance
- Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaGlobeNewswire
- Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics, Inc. (NASDAQ: WINT) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
WINT
Analyst Actions
- 12/4/24 - HC Wainwright
WINT
Sec Filings
- 12/5/24 - Form 8-K
- 12/4/24 - Form 8-K
- 11/27/24 - Form 8-K
- WINT's page on the SEC website